Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

¿Cómo transportar fármacos al cerebro para tratar patologías?La Vanguardia

How to transport drugs to the brain to treat pathologies?

El cerebro está protegido por la barrera hematoencefálica, que impide la entrada de bacterias, virus…
Read more

G2B receives funding to accelerate its transfer to the market and society

Gate2Brain, a spin-off of Sant Joan de Déu (SJD), Institute for Research in Biomedicine (IRB) Barcelona…
Read more
Cuatro proyectos biomédicos innovadores reciben el impulso de la Fundación ”la Caixa” para acelerar su llegada al mercado y a la sociedadFundació La Caixa

Four innovative biomedical projects boosted by the Fundació “la Caixa”

Cuatro proyectos biomédicos innovadores reciben el impulso de la Fundación ”la Caixa”…
Read more
Gate2Brain has been granted financial support by the CDTIGate2Brain

Gate2Brain has been granted financial support by the CDTI

At Gate2Brain we’re closing the year 2021 with good news and uplifted spirit!Gate2Brain has been…
Read more

Gate2Brain among the 11 most promising life & health sciences startups in Catalonia

Barcelona and Catalonia have turned into a leading life sciences hub. According to Catalonia Trade…
Read more
Meritxell Teixidó (Gate2Brain, Medicines Beyond Barriers): “Utilitzem una nova tecnologia basada en pèptids per millorar el transport de fàrmacs al cervell”

Meritxell Teixidó (Gate2Brain, Medicines Beyond Barriers): “We use a new technology based on peptides to improve the transport of drugs to the brain”

Meritxell Teixidó (Gate2Brain, Medicines Beyond Barriers): “Utilitzem una nova tecnologia basada en…
Read more
Líderes que van más allá de las barrerasTedxSitges

TedxSitges 2021 Leaders beyond barriers

On November 6, Meritxell Teixidó, CEO and Co-Founder of Gate2Brain participated in the first edition…
Read more
Gate2Brain abre una ronda puenteo de un millón de euros para ensayos preclínicoPlantaDoce

Gate2Brain opens one million euro bridge round for preclinical trials

Gate2Brain abre una ronda puente de un millón de euros para ensayos preclínicos La compañía prevé…
Read more
la start-up catalana una de las ganadoras del South Summit de salud en Valenciala Vanguardia

Gate2Brain one of the winners of the South Summit Health & Well-being

La start-up catalana Gate2Brain ha sido galardonada con el premio al proyecto más innovador en el South…
Read more
Innovatia 8.3

1st Innovatia 8.3 Investment Forum

Gate2Brain together with Integra Therapeutics, BICOSOME, BFlow, CAPTOPLASTIC, Genengine, MEETOPTICS and PlusVitech…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social